Antibody-Drug Conjugates – Special Topics – Special Topics: Antibody-Drug Conjugates (G7)
Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of antibody-drug conjugates continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates and analyzes the market trends and dynamics in a range of oncology indications.
QUESTIONS ANSWERED
What is the timeline and current landscape for approved antibody-drug conjugates? What are the trends in each key oncology indication?
How will emerging antibody-drug conjugates be positioned in the market? How will the indication-specific market trends and dynamics evolve?
What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, combination type, and geography? How will the market evolve over the 2021-2031 forecast period?
GEOGRAPHIES
United States, EU5, Japan.
EPIDEMIOLOGY
Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.
FORECAST
10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.
KEY DRUGS COVERED
Currently approved agents targeting HER2, TROP-2 and CD79b.
EMERGING THERAPIES
Phase III
PRODUCT DESCRIPTION
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.
Antibody-Drug Conjugates - Special Topics - Special Topics: Antibody-Drug Conjugates (G7)
Special topics antibody-drug conjugates, US, EU5, Japan, November 2022
Kiran Bountra
Kiran Bountra, M.Res., Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Bountra has a background in the biotechnology sector, specializing in target validation and small-molecule drug discovery. Before joining Clarivate, he worked as a senior scientist at OMass Therapeutics, with a focus on basal cell carcinoma and epilepsy programs. Previously, he trained as a structural biologist, researching the mechanisms of transport proteins involved in drug resistance. He holds a Ph.D. in biochemistry from Imperial College London.
Laura Vinuesa, D.V.M., M.Sc.
Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.
